Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer
Open Access
- 22 July 1997
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 94 (15) , 8132-8137
- https://doi.org/10.1073/pnas.94.15.8132
Abstract
The product of the WT1 Wilms tumor suppressor gene controls the expression of genes encoding components of the insulin-like growth factor and transforming growth factor β signaling systems. The role of these growth factors in breast tumor growth led us to investigate possible WT1 gene expression in normal and cancerous breast tissue. WT1 was detected by immunohistochemistry in the normal mammary duct and lobule, and the patterns of expression were consistent with developmental regulation. In a survey of 21 infiltrating tumors, 40% lacked immunodetectable WT1 altogether and an additional 28% were primarily WT1-negative. Cytoplasmic, but not nuclear, localization of WT1 was noted in some tumor cells and WT1 was detected, sometimes at high levels, in more-advanced estrogen-receptor-negative tumors. In this highly malignant subset, the tumor suppressor protein p53, which can physically interact with WT1, was also sometimes detected. WT1 mRNA was detected in normal and tumor tissue by reverse transcription-coupled PCR. Alternative splicing of the WT1 mRNA may regulate gene targeting of the WT1 protein through changes either in its regulatory or zinc-finger domains. The relative proportions of WT1 mRNA splice variants were altered in a random sample of breast tumors, providing evidence that different tumors may share a common WT1-related defect resulting in altered regulation of target genes.Keywords
This publication has 47 references indexed in Scilit:
- P53, apoptosis, and breast cancerJournal of Mammary Gland Biology and Neoplasia, 1996
- Experimental mammary epithelial morphogenesis in anin vivo model: Evidence for distinct cellular progenitors of the ductal and lobular phenotypeBreast Cancer Research and Treatment, 1996
- The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis.Genes & Development, 1995
- Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II)European Journal Of Cancer, 1993
- Wilms tumor genesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1993
- Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.Journal of Clinical Investigation, 1993
- Evidence for a positive role of transforming growth factor-β in human breast cancer cell tumorigenesisJournal of Cellular Biochemistry, 1993
- Regulation of mammary morphogenesis: Evidence for extracellular matrix-mediated inhibition of ductal budding by transforming growth factor-β1Developmental Biology, 1992
- Type 1 IGF receptor in human breast diseasesBreast Cancer Research and Treatment, 1992
- TGF-β1-induced inhibition of mouse mammary ductal growth: Developmental specificity and characterizationDevelopmental Biology, 1989